secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2025-09-02T23:59:59+00:00
Accession:  0001933414-25-000107
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys Therapeutics terminates ATM prospectus supplement, halts sales until new filing
--------------------------------------------------------------------------------

- Delivered written notice to BofA Securities and Evercore terminating prospectus supplement dated April 11, 2024.
- No further sales of common stock under the Sales Agreement will occur until a new prospectus supplement is filed.
- The underlying ATM Equity Offering Sales Agreement (March 21, 2024) remains in full force and effect.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000193341425000107/0001933414-25-000107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000193341425000107/mlys-20250902.htm
  HTML page:      https://secwatch.observer/filing/0001933414-25-000107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer